Clinical Trials Browser

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT04640779 2026-01-06

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

22 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT05675319 2026-01-05

AlloRelapseMM

Phase 3 Terminated

28 enrolled

Plasma cell

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

117 enrolled

Plasma cell

Multiple Myeloma

NCT02199665 2025-11-03

SINE

Phase 1 Completed

52 enrolled

Plasma cell

Multiple Myeloma

NCT06822972 2025-09-02

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

Phase 2 Recruiting

27 enrolled

Plasma cell

Multiple Myeloma

NCT05900882 2025-08-17

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2 Recruiting

35 enrolled

Plasma cell

Multiple Myeloma

NCT04717700 2025-03-18

SABLe

Phase 2 Active not recruiting

50 enrolled

Plasma cell

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

103 enrolled

Plasma cell

Multiple Myeloma

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

Phase 2 Recruiting

15 enrolled

Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

73 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT06225310 2025-01-16

KPT-IST-391

Phase 1 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT04756401 2024-09-26

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Phase 2 Active not recruiting

52 enrolled

Plasma cell

Multiple Myeloma

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Plasma cell

Multiple Myeloma, Recurrence

NCT05820763 2024-07-10

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT05422027 2024-06-17

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Phase 1/2 Recruiting

42 enrolled

Plasma cell

Multiple Myeloma

NCT06212596 2024-01-19

MUKtwelve

Phase 2 Completed

66 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT04877275 2023-12-06

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Phase 2 Unknown

50 enrolled

Plasma cell

Multiple Myeloma

NCT04519476 2023-10-31

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Phase 1 Unknown

22 enrolled

Plasma cell

Multiple Myeloma

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03944057 2023-06-15

MARCH

Phase 2 Completed

82 enrolled 9 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Phase 1 Completed

286 enrolled 26 charts

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02336815 2023-01-26